PolyPeptide Group AG (SWX:PPGN)
Switzerland · Delayed Price · Currency is CHF 25.30
+0.05 (0.20%)
At close: Nov 28, 2025
PolyPeptide Group AG Revenue
PolyPeptide Group AG had revenue of 167.10M EUR in the half year ending June 30, 2025, with 26.75% growth. This brings the company's revenue in the last twelve months to 368.85M, up 13.99% year-over-year. In the year 2024, PolyPeptide Group AG had annual revenue of 336.79M with 5.13% growth.
Revenue (ttm)
368.85M EUR
Revenue Growth
+13.99%
P/S Ratio
2.42
Revenue / Employee
270.81K EUR
Employees
1,362
Market Cap
834.68M CHF
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 336.79M | 16.42M | 5.13% |
| Dec 31, 2023 | 320.37M | 39.39M | 14.02% |
| Dec 31, 2022 | 280.98M | -1.15M | -0.41% |
| Dec 31, 2021 | 282.13M | 57.83M | 25.78% |
| Dec 31, 2020 | 224.30M | 20.88M | 10.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 44.95B |
| Sandoz Group AG | 8.42B |
| Alcon | 8.12B |
| Lonza Group AG | 7.09B |
| Galenica AG | 4.03B |
| Sonova Holding AG | 3.85B |
| Galderma Group AG | 3.73B |